Carmustine, Dibromodulcitol, and Procarbazine (CDP) Combination

The combination of carmustine, dibromodulcitol, and procarbazine is a chemotherapy regimen that has been studied for the treatment of brain tumors, particularly recurrent glioblastoma and anaplastic astrocytoma. Let me provide you with comprehensive information about this drug combination. ## Composition and Classification This is a combination chemotherapy regimen consisting of three distinct alkylating agents. Each component has its own mechanism of action, though they all ultimately damage DNA and prevent cancer cell division. Carmustine (also known as BCNU or BiCNU) is an alkylating agent that causes cross-links in DNA and RNA, inhibiting DNA synthesis, RNA production, and protein synthesis[5]. It also binds to and modifies glutathione reductase, leading to cell death[5]. Dibromodulcitol is another alkylating agent that has been studied in combination with the other drugs for treating recurrent brain tumors[1]. Procarbazine is a chemotherapy medication that works by slowing or stopping the growth of cancer cells[10]. It's classified as a "nonclassical" oral alkylating anticancer agent that was first synthesized in the late 1950s[8]. ## Clinical Use This specific three-drug combination has been studied in phase II clinical trials for recurrent glioblastoma and anaplastic astrocytoma[1]. The combination showed some efficacy in these difficult-to-treat brain cancers. Procarbazine is also commonly used in other combination regimens: - With lomustine (CCNU) and vincristine (PCV) for treating gliomas[4][7] - In the BEACOPP regimen for Hodgkin lymphoma[7] - In the MOPP regimen, which was the first combination chemotherapy developed for Hodgkin lymphoma[7] Carmustine is used in the treatment of various malignancies including brain tumors and multiple myeloma[5][6]. ## Administration The administration of this combination typically involves: - Carmustine: Given through intravenous (IV) infusion[6] - Dibromodulcitol: Oral administration - Procarbazine: Taken orally as capsules[4][10] ## Side Effects Common side effects of this combination may include: - Low blood cell counts (leukopenia, thrombocytopenia)[5] - Nausea and vomiting[5][7] - Fatigue and tiredness[7] - Depression (particularly with procarbazine)[7] Carmustine specifically can cause pulmonary fibrosis and bone marrow toxicity[5]. ## Current Status While this specific three-drug combination has been studied in clinical trials, more recent approaches to treating malignant gliomas have focused on other combinations, particularly those including temozolomide[9]. The combination of carmustine, dibromodulcitol, and procarbazine represents an older approach to treating these challenging brain tumors. Research continues to evaluate various chemotherapy combinations for malignant gliomas, as these tumors remain difficult to treat effectively with current therapies.